



**Canadian  
Cardiovascular  
Society**

**MYCOVACC**

The CCS National Active Surveillance Study of **MY**ocarditis and/or Pericarditis following mRNA **COVID-19 VACC**ination (MYCOVACC) is a multi-centre, pan-Canadian study, funded by the Public Health Agency of Canada (PHAC) from Sept. 1, 2022, to March 31, 2026. The CCS wishes to thank PHAC for financial support for this project.

---

## **Four-Year Study of COVID-19 Vaccines Brings New Insights, Valuable Data, Expanded Collaboration**

*This pan-Canadian initiative, led by the CCS, began during the global pandemic in 2022 amid reports of rare cases of myopericarditis after mRNA COVID-19 vaccination.*

OTTAWA \_ A four-year national cardiovascular surveillance study on the long-term impact of mRNA COVID-19 vaccination, funded by the Public Health Agency of Canada, has produced valuable insights, a rich repository of data, and new directions for research.

[Read the News Release Here](#)

---

## **Study Update**

MYCOVACC recruited 34 adult and pediatric study sites from across Canada with assistance from key research partner networks, including the Canadian Congenital and Pediatric Cardiology Research Network (CCPCRN) and COVID-19 Vaccine-induced Inflammatory Heart Disease Registry (COVID-VIHPR).

Five hundred patients with post-vaccine myopericarditis and 100 patients with post-COVID-19 myopericarditis participated in the study. In addition to the main study addressing long-term clinical and functional outcomes, MYCOVACC sub-studies focused

on adverse event reporting following immunization, convalescent cardiac magnetic resonance imaging, and patch arrhythmia monitoring.

Funding from PHAC ended on March 31, and participant recruitment is closed. Publications are planned for this year and next. Clinical resources and information for patients and health-care providers will continue to be available on the CCS website [here](#).

---

## Recent Conference Presentations

- McDonald, M., Luk, A., Janjua, N., Hira, R., Huynh, T., Raj, S., Khoury, M., & Hawkins, N. (2025, October 24). *Managing the Cardiovascular Consequences of the COVID-19 Pandemic: Applying Emerging Evidence in Cardiology Practice*. [Workshop]. Canadian Cardiovascular Congress, Québec City, Québec, Canada.
- Capeline, L.S., Marianchuk, R., Labib, D., Tse, J.J., Beckie, T.A., Haufe, K., Jensen, C., El Ferri, O., Rivest, S., Flewitt, J., Pullen, C., McDonald, M., Kafil, T., Wright, M., Hawkins, N., Hanneman, K., & White, J.A. (2026, February 6). *Comparison of COVID-19 Vaccine Associated Myocarditis and Non-COVID Viral Myocarditis – Preliminary Findings from the MYCOVACC Cardiac MRI Sub-study*. [Presentation]. Society of Cardiovascular Magnetic Resonance Scientific Session, Rio de Janeiro, Brazil.

---

## Learn: Two New MYCOVACC Courses Available on CardioCampus

You can now access two MYCOVACC continuing professional development resources from the new CCS CardioCampus platform. If you are not a CCS member or don't yet have a [my.ccs.ca](https://my.ccs.ca) guest account, you can open one [now](#).

### Section 3 Course: Unmasking the Cardiac Legacy of COVID-19: Insights and Impacts in 2025

Myocarditis and  
Pericarditis after mRNA  
COVID-19 Vaccination



This online MOC Section 3 accredited self-assessment program addresses the acute and chronic cardiovascular effects of COVID-19 infection as well as the benefits and risks associated with mRNA COVID-19 vaccination. Dr. Anil Gupta chairs the session. Panelists are Dr. Naveed Janjua, Dr. Thao Huynh, Dr. Satish Raj, and Dr. Nathaniel Hawkins.

[Access the Course](#)

## Recording: Beyond the Acute Phase: Cardiac MRI Insights from the CCS National Active Surveillance Study of Myocarditis and/or Pericarditis following mRNA COVID-19 Vaccination

Recorded  
Program



This CCS continuing professional development webinar updates the cardiovascular community on results from the Canadian Cardiovascular Society National Active Surveillance Study of **MY**ocarditis and/or Pericarditis following mRNA **COVID-19 VACC**ination (MYCOVACC) with particular focus on cardiac magnetic resonance imaging findings. Dr. Aws Almufleh chairs the session. Panelists are Dr. Nathaniel Hawkins, Dr. James White, and Dr. Lorena Capeline.

[Access the Recording](#)

---

## Thanks to MYCOVACC Investigators and Participating Sites

The CCS mobilized its network of more than 2,500 members, as well as cardiac centres and partner organizations across Canada, as part of the MYCOVACC study. The CCS is grateful to Dr. Nathaniel Hawkins for his exceptional leadership of the project as well as Dr. Richard Bennett, Dr. Lorena Capeline, Dr. Frédéric Dallaire, Dr. Kate Hanneman, Dr. Naveed Janjua, Dr. Tahir Kafil, Dr. Michael Khoury, Dr. Michael McDonald, Dr. Peter Liu, Dr. Adriana Luk, and Dr. James White for their important scholarly contributions.



The CCS also wishes to acknowledge the support of colleagues at the participating sites:

- MYCOVACC sites - Vancouver General Hospital, St Paul's Hospital, Royal Inland Hospital, Royal Jubilee Hospital, Royal Columbian Hospital, University of Calgary, University of Alberta, University Health Network, Unity Health, Sunnybrook Health Sciences Centre, Cardio Pulmonary Services (Waterloo), McGill University, Centre hospitalier universitaire (CHU) de Quebec, Montreal Heart Institute, and Prairie Vascular Research Inc.
- CCPCRN sites- CHU de Sherbrooke, CHU de Quebec, McGill University, CHU Sainte Justine, Alberta Children's Hospital, Stollery Children's Hospital, British Columbia Children's Hospital, Children's Hospital of Eastern Ontario, McMaster Children's Hospital, The Hospital for Sick Children, St. Joseph's Health Care London, and Kingston Health Sciences Centre.
- COVID-VIHPR sites - University of Ottawa Heart Institute, Kingston Health Sciences Centre, London Health Sciences Centre, Michael Garron Hospital, Scarborough Health Network, Dalhousie University, and St. Boniface Hospital.

---


## MYCOVACC Recognizes Enormous Leadership Contributions of Committee Members

Three key committees made up the governance structure of the MYCOVACC study, including the 15-member **Steering Committee** chaired by Dr. Nathaniel Hawkins and Dr. Carolyn Pullen, eight-member **Scientific Data and Management Committee** chaired by Dr. James White, and seven-member **Integrated Knowledge Translation Committee** chaired by Dr. Michael McDonald.

Thanks to all those who participated in these committees, guided the initial design and ongoing management of the project, supported development of tools and resources, and

ensured scientific excellence throughout the four-year study. CCS also extends special thanks to Dr. Meredith Wright for her outstanding project management contribution.

## Canadian Cardiovascular Society (CCS) National Active Surveillance Study on Myocarditis and/or Pericarditis following mRNA COVID-19 Vaccination (MYCOVACC) Governance Structure



**Steering Committee** – Guides project implementation, operations, and financial management. Accountable to the CCS Board.

**Integrated Knowledge Translation (IKT) Committee** – Develops and supports implementation of the Integrated Knowledge Translation strategy.

**Scientific & Data Management Committee** – Ensures high-quality data and ethical data collection, storage, and use; reviews all protocols, publications, and reports.

---

Email: [mycovacc@ccs.ca](mailto:mycovacc@ccs.ca)

Website: <https://ccs.ca/mycovacc/>

*Financial contribution from*



Public Health  
Agency of Canada

Agence de la santé  
publique du Canada



[Please click here to opt out of this mailing or to change your CCS communication preferences.](#)

Canadian Cardiovascular Society | 1000-150 Elgin Street | Ottawa, ON K2P 1L4 CA

[Unsubscribe](#) | [Constant Contact Data Notice](#)